Carl Zeiss AG has appointed Bronwyn Brophy O’Connor as the new Executive Board Member responsible for the company’s Medical Technology segment, while the Supervisory Board of Carl Zeiss Meditec has named her Chief Executive Officer of the publicly listed medical technology company.

Andreas Pecher, President and CEO of Carl Zeiss AG, has served as interim CEO of Carl Zeiss Meditec AG since January 2026 and will continue in the role until Brophy O’Connor officially assumes her position. The exact start date remains subject to ongoing negotiations and will be announced at a later stage.

Ms. Brophy O’Connor currently serves as CEO of the Vitrolife Group, a Gothenburg, Sweden-based company listed on NASDAQ Stockholm in Sweden. She brings more than 25 years of international leadership experience across the medical technology and life sciences sectors.

Over the course of her career, she has held senior leadership positions at major multinational healthcare companies including Thermo Fisher Scientific, Medtronic, and Johnson & Johnson. Her professional experience spans several international markets, including the United Kingdom, Ireland, Switzerland, Spain, and the United States.

“With Bronwyn Brophy O’Connor, we are pleased to have found a successor who has excelled internationally,” said Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG. “She has over 25 years of professional experience in medical technology and life sciences and, with her exceptional capabilities, will play a key role in shaping the ongoing realignment of Zeiss Medical Technology. We wish her a great start and all the best for her new position at Zeiss."